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Aim
Nucleotide analogues such as Azidothymidine-triphosphate
(AZT-TP), the active form of Zidovudine, display an impor-
tant pharmacological activity for the treatment of HIV. The
administration of these nucleotide analogues would bypass
the intracellular phosphorylation which can be a metabolic
bottleneck. This possibility is however limited by their
instability in physiological conditions, and furthermore
their hydrophilicity restricts their access to the target cells.
Several nanocarriers have been proposed so far for the
encapsulation of these molecules, but their applications are
limited due to the low drug loading achieved. Our strategy
proposes the use of chitosan, a biocompatible and hydro-
philic polysaccharide which is known to form nanoparticles
through complexation with TPP; in contrast with previous
methods, in our case the drug itself will be the driving force
for the formation of nanoparticles [1].
Material and methods
Different molar ratios between chitosan and AZT-TP (or
ATP, used here as a model drug) have been tested in order
to study the formation of nanoparticles; some selected
ratios have been then evaluated for their size, surface prop-
erties, drug encapsulation and loading. In vitro cell uptake
experiments were performed on a cell line of macrophages,
using the free molecule as a negative control. The intracel-
lular distribution of the delivered molecules was further
investigated using confocal laser microscopy.
Results
Colloidal suspensions have been obtained from chitosan
and AZT-TP; nanoparticles present a minimal size
about 200 nm with a zeta potential above +20 mV. An
encapsulation efficiency of 70% can be reached, allowing
loading rates as high as 44%. A cell viability of 80% has
been found for particle concentrations up to 0.6 mg/mL.
The cellular uptake is at least 2-fold higher when mole-
cules are delivered as nanoparticles, compared to the
free molecules.
Conclusions
An original method is proposed to design nanoparticles,
which allows high loading rates; this lowers the amounts
of excipients needed, thus limiting the toxicity concerns.
These nanosystems allow an efficient in vitro intracellular
delivery of nucleotide analogues. Further in vivo studies
will investigate the potential of these nanocarriers.
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